Share on LinkedInShare on LinkedIn

ARTICLE · 07 JULY 2022

FTC And DOJ Workshop On Pharmaceutical Mergers Highlights Potential For Heightened Scrutiny By Enforcers

The U.S. Federal Trade Commission (FTC) and Department of Justice, Antitrust Division (DOJ) recently hosted a two-day virtual workshop titled "The Future of Pharmaceuticals: Examining the Analysis...

United StatesAntitrust/Competition Law

The U.S. Federal Trade Commission (FTC) and Department of Justice, Antitrust Division (DOJ) recently hosted a two-day virtual workshop titled "The Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers." The workshop followed the agencies' creation of a Multilateral Pharmaceutical Merger Task Force in March 2021 and an invitation for public comments concerning potential changes to analysis of pharmaceutical mergers. The FTC and DOJ are also currently in the process of revising their general merger guidelines, and the antitrust community is expecting significant revisions to their past analytic approach (see our prior coverage here).

The workshop took a broad view of the effect of pharmaceutical mergers, highlighting potential effects and theories of harm that have not historically been a focus of merger reviews. Overall, the panelists chosen for the workshop highlighted voices that largely favored increased scrutiny of pharmaceutical mergers,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from